At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 80 enrolled
Drug / intervention
Ciclesonide +1 moredrug
Likely dose
Ciclesonide 50 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-Center, Double-Blind, Placebo-Controlled, Two-Arm, Parallel-Group, Phase III (Registration) Study to Assess the Efficacy and Safety of Ciclesonide Nasal Spray (Omnaris®) 200 mcg Once Daily in the Treatment of the Patients With Seasonal Allergic Rhinitis (SAR) in Russia
In Brief
A Phase 3 clinical trial evaluating Ciclesonide and Ciclesonide Placebo for Seasonal Allergic Rhinitis. Completed, enrolled 80 participants across 5 sites.
Detailed Summary
The purpose of this study is to explore the efficacy and safety of Ciclesonide Nasal Spray 200 microgram (mcg) once daily in the treatment of seasonal allergic rhinitis (SAR) in Russian participants.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSeasonal Allergic Rhinitis
CountriesRussia
Collaborators--
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJun 2014
Enrollment StartAug 2014
Primary CompletionOct 2014
Study CompletionNov 2014
TodayJul 2026
First PostedJun 4, 2014
Enrollment StartAug 1, 2014
Primary CompletionOct 1, 2014
Study CompletionNov 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 12.1 years ago
Interventions
Ciclesonidedrug
Ciclesonide nasal spray 50 mcg/actuation
Ciclesonide Placebodrug
Ciclesonide placebo-matching nasal spray